Savara Reports Fourth Quarter / Year-End 2019 Financial Results and Provides Business Update

Go back to Savara Reports Fourth Quarter / Year-End 2019 Financial Results and Provides Business Update

Savara (SVRA) Misses Q4 EPS by 31c

March 12, 2020 4:34 PM EDT

Savara (NASDAQ: SVRA) reported Q4 EPS of ($0.72), $0.31 worse than the analyst estimate of ($0.41).

Results from the open-label period of IMPALA reaffirm our strong belief that Molgradex could improve outcomes for patients with aPAP, a rare and debilitating lung disease, said Rob Neville, Chief Executive... More